imatinib actavis
actavis group ptc ehf - το imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. Η δράση του imatinib σχετικά με την έκβαση της μεταμόσχευσης μυελού των οστών δεν έχει καθοριστεί. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. Η εμπειρία με imatinib σε ασθενείς με mds/mpd που σχετίζονται με γονιδιακές αναδιατάξεις του pdgfr είναι πολύ περιορισμένη. Δεν υπάρχουν ελεγχόμενες μελέτες που να καταδεικνύουν κλινικό όφελος ή αυξημένη επιβίωση για αυτές τις ασθένειες.
ozapram 10mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 10mg - olanzapine (8000001532) 10mg - olanzapine
ozapram 20mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 20mg - olanzapine (8000001532) 20mg - olanzapine
ozapram 5mg film coated tablets
remedica ltd (0000003171) aharnon str., lemesos, 3056 - olanzapine - film coated tablets - 5mg - olanzapine (8000001532) 5mg - olanzapine
lipidil nt 145mg film coated tablets
viatris healthcare limited. (0000012172) damastown industrial park, mulhuddart, dublin 15, d15 xd71 - fenofibrate - film coated tablets - 145mg - fenofibrate (0049562289) 145mg - fenofibrate
pamidronate disodium
pharmaceutical trading co ltd - ΤΟ pamidronate disodium - solution for infusion, concentrate for - 90mg/10ml - 8000001289 - disodium pamidronate - 9 mg base - pamidronic acid
selegos 5mg tablets
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - selegiline hydrochloride - tablets - 5mg - selegiline hydrochloride (0014611520) 5mg - selegiline
medobeta 0.1% w/w ointment
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - betamethasone valerate - ointment - 0.1% w/w - betamethasone valerate (0002152445) 1,22mg - betamethasone
medocef 1g/vial powder for solution for injection/infusion
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - cefoperazone sodium - powder for solution for injection/infusion - 1g/vial - cefoperazone sodium (0062893203) 1,0344g - cefoperazone
medodermone 0.05% w/w ointment
medochemie ltd (0000003169) 1-10 constantinoupoleos str, lemesos, 3011, 51409 (3505) - clobetasol propionate - ointment - 0.05% w/w - clobetasol propionate (0025122467) 0,5mg - clobetasol